###begin article-title 0
###xml 33 40 33 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF2BP2</italic>
Evaluation of the Association of IGF2BP2 Variants With Type 2 Diabetes in French Caucasians
###end article-title 0
###begin p 1
###xml 39 69 39 69 <email xmlns:xlink="http://www.w3.org/1999/xlink">fernando.gibson@imperial.ac.uk</email>
Corresponding author: Fernando Gibson, fernando.gibson@imperial.ac.uk
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit,and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE&#8212;</bold>
###xml 98 105 98 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF2BP2</italic>
OBJECTIVE-We performed a comprehensive genetic association study of common variation spanning the IGF2BP2 locus in order to replicate the association of the "confirmed" type 2 diabetes susceptibility variants rs4402960 and rs1470579 in the French Caucasian population and to further characterize the susceptibility variants at this novel locus.
###end p 3
###begin p 4
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS&#8212;</bold>
###xml 108 115 108 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF2BP2</italic>
RESEARCH DESIGN AND METHODS-We genotyped a total of 21 tagging single nucleotide polymorphisms spanning the IGF2BP2 locus in our type 2 diabetes case-control cohort comprising 3,093 French Caucasian subjects.
###end p 4
###begin p 5
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESULTS&#8212;</bold>
###xml 112 113 112 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 126 127 126 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 626 627 626 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 796 797 796 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 809 811 809 811 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;6</sup>
###xml 851 852 851 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
RESULTS-IGF2BP2 variants rs4402960 and rs1470579 were not associated with type 2 diabetes in the present study (P = 0.632 and P = 0.896, respectively). Meta-analysis of genotype data from over 34,000 subjects demonstrated that our inability to replicate rs4402960/rs1470579 was consistent with the findings from several previous genome-wide association study (GWAS) datasets that were underpowered to detect this modest association signal (odds ratio [OR] 1.14). We obtained novel evidence that rs9826022, a borderline rare variant (5% minor allele frequency) in the 3' downstream region, was associated with type 2 diabetes (P = 0.0002; OR 1.53 [95% CI 1.22-1.91]). This result was corroborated by the meta-analysis of 10,542 genotypes from the current study and GWAS datasets using both fixed (P = 9.47 x 10-6; 1.30 [1.16-1.46]) and random effects (P = 0.001; 1.30 [1.11-1.52)] calculations.
###end p 5
###begin p 6
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS&#8212;</bold>
###xml 173 180 173 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF2BP2</italic>
###xml 262 269 262 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF2BP2</italic>
CONCLUSIONS-We were unable to replicate the confirmed rs4402960/rs1470579 susceptibility variants but found novel evidence for a rare variant in the 3' downstream region of IGF2BP2. Further genetic and functional studies are required to identify the etiological IGF2BP2 variants.
###end p 6
###begin p 7
Published ahead of print at  on 22 April 2008.
###end p 7
###begin p 8
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 8
###begin p 9
###xml 57 64 57 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF2BP2</italic>
###xml 106 113 106 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF2BP1</italic>
###xml 136 140 136 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF2</italic>
###xml 272 273 272 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 328 329 328 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 376 377 376 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 464 471 464 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF2BP2</italic>
###xml 665 672 665 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF2BP2</italic>
###xml 764 765 764 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 766 767 766 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 809 810 809 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 837 844 837 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF2BP2</italic>
###xml 914 915 914 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 947 954 947 954 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF2BP2</italic>
###xml 987 994 987 994 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF2BP2</italic>
###xml 1221 1228 1221 1228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF2BP2</italic>
The insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2) gene on chromosome 3q27 is a paralog of IGF2BP1, a known regulator of IGF2 gene expression. Genome-wide association studies (GWASs) carried out by the Finland-U.S. Investigation of NIDDM Genetics (FUSION) (1), the Wellcome Trust Case Control Consortium (WTCCC) (2), and the Diabetes Genetics Initiative (DGI) (3) groups each found modest evidence that single nucleotide polymorphisms (SNPs) in the IGF2BP2 region are associated with type 2 diabetes. The subsequent meta-analysis of primary and replication datasets from these GWASs corroborated these findings and identified two strongly correlated IGF2BP2 variants, rs1470579 and rs4402960, as "confirmed" type 2 diabetes susceptibility variants (1-3). By contrast, the French/Canadian GWAS (4) typed 10 SNPs across the IGF2BP2 locus, including rs1470579, in 1,363 subjects, but found no nominal (P < 0.05) association signals at IGF2BP2. In an attempt to replicate the IGF2BP2 association findings in the French Caucasian population in a larger study and to further characterize the susceptibility variants at this novel locus, we performed an association study of HapMap Phase II tag SNPs spanning the IGF2BP2 locus in 3,093 French Caucasian subjects.
###end p 9
###begin title 10
RESEARCH DESIGN AND METHODS
###end title 10
###begin p 11
###xml 89 90 89 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 335 336 335 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 370 371 370 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1</italic>
###xml 410 411 410 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 438 439 438 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 575 576 575 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1</italic>
###xml 635 636 635 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 766 767 766 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 774 775 774 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3</italic>
###xml 960 961 960 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 221 229 <span type="species:ncbi:9606">patients</span>
###xml 447 455 <span type="species:ncbi:9606">patients</span>
All subjects were of French Caucasian ancestry. Individuals identified by Sladek et al. (4) as lying outside the HapMap CEU ancestry cluster were excluded from the study. Type 2 diabetic case subjects were known diabetic patients. Normoglycemic control subjects were selected to have a fasting blood glucose concentration <7.0 mmol/l (5). Case subjects were composed of 1) 372 probands from diabetic families (6), recruited in Lille; and 2) 1,083 patients with a family history of type 2 diabetes, recruited at the Corbeil-Essonne Hospital. Control subjects were composed of 1) 353 normoglycemic parents from type 2 diabetic families; 2) 543 subjects from the SUVIMAX (Supplementation en Vitamines et Mineraux Antioxidant) prospective population-based cohort study (7); and 3) 742 subjects selected from the DESIR (Data from an Epidemiologic Study on the Insulin Resistance Syndrome) cohort, a large prospective study of insulin resistance in French subjects (8). Informed consent was obtained from all subjects, and the study was approved by local ethics committees.
###end p 11
###begin title 12
Statistical power.
###end title 12
###begin p 13
###xml 108 109 104 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 214 215 206 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 284 285 272 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 471 472 459 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 473 474 461 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
The case-control cohort comprised 1,455 type 2 diabetic subjects (age 60 +/- 12 years, BMI 29.0 +/- 6.0 kg/m2, sex [male:female] 56:44%) and 1,638 normoglycemic subjects (aged 54 +/- 13 years, BMI 24.1 +/- 3.3 kg/m2, sex 43:57%). At alpha = 0.05, this sample size provided 76% power (9) to detect the type 2 diabetes susceptibility variants rs1470579 and rs4402960, assuming an allele frequency of 0.30, a disease prevalence of 0.1, a heterozygote relative risk of 1.14 (1-3), a multiplicative model, and a 100% genotype call rate.
###end p 13
###begin title 14
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF2BP2</italic>
IGF2BP2 tag SNP selection.
###end title 14
###begin p 15
###xml 105 112 105 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF2BP2</italic>
###xml 247 248 247 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 248 249 248 249 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 437 438 437 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 439 440 439 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
The genomic target region for tag SNP selection was extended 10 kb upstream and downstream of the NCBI36 IGF2BP2 locus (chr. 3:186,844,221.0.187,025,521). A total of 19 HapMap Phase II multimarker tagging SNPs (HapMap Data Release 21a/Jan07) with r2 and minor allele frequency thresholds of 0.8 and 0.05, respectively, were identified for genotyping. In addition, the two GWAS-identified susceptibility variants rs4402960 and rs1470579 (1-3) were added to the genotyped SNP set, making a total of 21 genotyped SNPs.
###end p 15
###begin title 16
SNP genotyping.
###end title 16
###begin p 17
###xml 67 69 67 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 165 166 163 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 274 275 272 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Genotyping was performed with the Sequenom MassARRAY iPLEX system (10). SNP genotype frequencies were tested for accordance with Hardy-Weinberg equilibrium using chi2 analysis. Regarding quality control, all 21 genotyped SNPs exhibited a call rate >90% and a Hardy-Weinberg P > 0.05, with well-defined genotype clusters. There was no evidence (at alpha = 0.01) of differential call rates across case and control subjects for any SNP (supplementary Table 2 [available in an online appendix at ]).
###end p 17
###begin title 18
Statistical analyses.
###end title 18
###begin p 19
###xml 27 34 27 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF2BP2</italic>
###xml 65 66 63 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 246 248 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 753 754 751 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 984 985 982 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Q</italic>
###xml 1004 1005 1002 1003 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 1005 1006 1003 1004 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1015 1017 1013 1015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 1018 1020 1016 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 1138 1140 1136 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 1250 1252 1248 1250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 1338 1340 1336 1338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
To test for association of IGF2BP2 SNPs with type 2 diabetes, chi2 analysis of allele and genotype counts was performed. Pairwise SNP linkage disequilibrium (LD) values were calculated from the genotype data of the control cohort with Haploview (11). Quantitative metabolic phenotypes, BMI, waist-to-hip ratio, fasting serum levels of triacylglycerol, total and HDL cholesterol, glucose, insulin, apolipoprotein A-I (ApoA1), and apolipoprotein B (ApoB), measured in 1,539 normoglycemic subjects from the control cohort, were log transformed and adjusted for age, sex, and BMI, as appropriate. SNPs were tested for association with adjusted quantitative traits using SPSS 14.0 with the ANOVA test under a codominant model. Quantitative trait association P values are presented uncorrected for multiple testing. Combined analysis of association datasets was carried out with the Mantel-Haenszel (fixed effects) meta-analysis method. Interstudy heterogeneity was assessed with Cochran's Q statistic and the I2 metric (12,13). All calculations were performed using R (version 2.5.1) statistical software and the Meta (version 0.8-2) package (14). Association analysis of SNPs captured by multimarker tags was carried out with the PLINK software package (15). Haplotype association was performed with the WHAP (version 2.09) software package (16).
###end p 19
###begin title 20
RESULTS AND DISCUSSION
###end title 20
###begin p 21
###xml 52 53 52 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 53 54 53 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 109 116 105 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF2BP2</italic>
###xml 374 382 370 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Figure 1</xref>
###xml 449 450 445 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 450 451 446 447 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 488 489 484 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 490 491 486 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 510 512 506 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 655 656 651 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 677 678 673 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 783 790 779 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 857 858 853 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 879 880 875 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 906 907 902 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
A total of 21 HapMap Phase II multimarker tag SNPs (r2 >/= 0.8; minor allele frequency >/=0.05) spanning the IGF2BP2 locus, including the susceptibility variants rs4402960 and rs1470579, were tested for association with type 2 diabetes in 3,093 French subjects. The allele and genotype counts for all SNPs are presented in online supplementary Tables 1 and 2, respectively. Figure 1 shows that SNPs rs4402960 and rs1470579 exhibited very strong LD (r2 = 0.95) in agreement with the GWAS (1-3) and HapMap data (17). However, the allele frequencies of SNPs rs4402960 and rs1470579 were not significantly different in the case and control groups (rs4402960, P = 0.632; rs1470579, P = 0.896), indicating that these variants were not associated with type 2 diabetes in the present study (Table 1). None of the three SNPs captured by multimarker tags (rs4575929, P = 0.159; rs4686692, P = 0.566; and rs16860216, P = 0.972;) were associated with type 2 diabetes (online supplementary Table 3).
###end p 21
###begin p 22
###xml 226 227 226 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 232 233 232 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 220 233 220 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic> and <italic>B</italic></xref>
###xml 836 837 834 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 848 851 846 849 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;14</sup>
###xml 1169 1170 1167 1168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1181 1183 1179 1181 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;9</sup>
Our inability to replicate the confirmed rs4402960/rs1470579 association result can be attributed to a lack of power to detect this modest signal. An examination of the published association evidence for these variants (Fig. 2A and B and online supplementary Tables 4 and 5) illustrates this point and demonstrates that our results are not inconsistent with those of previous studies. Of the nine published rs4402960 datasets, the three statistically well-powered studies (those with >/=90% power) all obtained an association for this variant, while the six underpowered studies showed either no association or a weak association with type 2 diabetes. Overall, the combined data shows a 3% difference in allele frequency between the case and control groups in over 34,000 subjects, which equates to very strong evidence of association (P = 1.9 x 10-14; OR 1.13 [95% CI 1.10-1.17]). Similarly for the rs1470579 variant, the underpowered datasets were either nonsignificant or weakly associated with type 2 diabetes. The combined data shows a 2% allele frequency difference in over 22,000 case-control subjects and a clearly significant association with type 2 diabetes (P = 2.6 x 10-9; 1.13 [1.09-1.18]). All of this serves as a reminder that the meta-analysis of individually underpowered studies has an invaluable role to play in the identification and confirmation of susceptibility variants of small effect.
###end p 22
###begin p 23
###xml 39 40 39 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 40 41 40 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 43 45 43 45 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 46 48 46 48 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 95 96 95 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 89 96 89 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>D</italic></xref>
###xml 141 142 141 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 142 143 142 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 287 288 287 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 300 302 300 302 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;8</sup>
###xml 429 430 429 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 430 431 430 431 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 474 475 474 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 518 519 518 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 531 533 531 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;9</sup>
###xml 549 550 549 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Q</italic>
###xml 597 598 597 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
The between-study heterogeneity metric I2 (12,13) was calculated for these two variants (Fig. 2D). Heterogeneity was moderate for rs4402960 (I2 = 21%) in agreement with a recent study (18). For rs1470579, the meta-analyzed signal is clearly driven by the DGI Replication set "S" result (P = 3.73 x 10-8). In accordance with this standout result and the smaller number of studies available for this SNP, heterogeneity was higher (I2 = 58%); the random effects OR gave a mere P = 0.001 compared with the Mantel-Haenszel P = 2.56 x 10-9; and Cochran's Q statistic was also statistically significant (P = 0.037).
###end p 23
###begin p 24
###xml 71 72 71 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 148 155 148 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 241 242 241 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 446 447 446 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 447 448 447 448 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 489 490 489 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 483 490 483 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>C</italic></xref>
###xml 601 602 601 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 675 676 675 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 688 690 688 690 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;6</sup>
###xml 753 754 753 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 754 755 754 755 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
We obtained novel evidence that rs9826022 in the 3' downstream region (P = 0.0002; OR 1.53 [95% CI 1.22-1.91]) was associated with type 2 diabetes (Table 1). This result survived Bonferroni correction for the number of SNPs tested (adjusted P = 0.003), and we sought confirmation in the publicly available GWAS data. The WTCCC () and DGI () GWAS did not directly type the rs9826022 variant but instead typed rs9878208, an rs9826022 proxy (HapMap r2 = 1). Meta-analysis of this data (Fig. 2C and online supplementary Table 6) provided support for the association, although the random effects evidence (P = 0.001) was weaker than that produced by the Mantel-Haenszel analysis (P = 9.47 x 10-6). The heterogeneity between these three studies was moderate (I2 = 44%). The disparity between the fixed and random effects may indicate that rs9826022 is not the "causative" variant but merely in partial LD with the true susceptibility variant; or it may simply reflect the "winner's curse" result of the present study and the inherently larger variance of the genetic effect of rare variants in moderately sized studies. The rs9826022 result will clearly require confirmation in further large, independent studies before a definitive assessment of the contribution of this rare variant to type 2 diabetes susceptibility can be made.
###end p 24
###begin p 25
###xml 54 55 54 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 207 208 207 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 208 209 208 209 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 374 375 374 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 712 715 <span type="species:ncbi:9606">men</span>
###xml 720 725 <span type="species:ncbi:9606">women</span>
The only other nominal association signal, rs9864104 (P = 0.012; OR 1.19 [95% CI 1.04-1.37]), was modest and disappeared upon multiple test correction. Since rs9826022 and rs9864104 were in low-moderate LD (r2 = 0.26), we carried out haplotype analysis of these variants. Two SNP haplotypes containing the rare allele of rs9826022 showed a virtually identical frequency and P value as the single-point rs9864104 analysis (online supplementary Table 7), indicating that the haplotype analysis did not add anything to the single-point analysis and that the weak rs9864104 signal was caused by this variant being in partial LD with rs9826022. There were no significant differences in SNP allele frequencies between men and women, and no association with type 2 diabetes was uncovered by stratifying for sex (data not shown).
###end p 25
###begin p 26
###xml 237 238 237 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 314 315 314 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 342 343 342 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 443 450 443 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF2BP2</italic>
SNPs rs4402960, rs1470579, rs9826022, and rs9864104 were also tested for association with a number of metabolic quantitative phenotypes (online supplementary Table 8). SNPs rs4402960 and rs1470579 presented weak associations with ApoA1 (P = 0.019 and 0.028, respectively). SNP rs9864104 was associated with ApoA1 (P = 0.008) and ApoB levels (P = 0.002), although there was no linear trend between the three genotype groups. The association of IGF2BP2 variation with apolipoprotein levels may be consistent with the role of the insulin-like growth factor system in regulating lipid metabolism. However, in the absence of replication, we emphasize that these quantitative trait associations are of nominal significance and require confirmation in further large studies.
###end p 26
###begin p 27
###xml 102 109 102 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF2BP2</italic>
###xml 323 330 323 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF2BP2</italic>
###xml 428 435 428 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF2BP2</italic>
In conclusion, we have carried out a comprehensive association study of common variation spanning the IGF2BP2 locus and type 2 diabetes in French Caucasians. We were unable to replicate the confirmed susceptibility variants rs4402960 and rs1470579 but found novel evidence for a rare variant in the 3' downstream region of IGF2BP2. Further genetic and functional studies are required to identify the etiological variants at the IGF2BP2 locus and to determine the cellular and physiological mechanisms by which they act to modulate type 2 diabetes susceptibility.
###end p 27
###begin title 28
Supplementary Material
###end title 28
###begin title 29
Online-Only Appendix
###end title 29
###begin p 30
This work was supported by a Wellcome grant to F.G. (WT081510MA).
###end p 30
###begin p 31
We thank the anonymous referees and editorial staff for critically appraising and improving draft versions of the manuscript.
###end p 31
###begin title 32
REFERENCES
###end title 32
###begin p 33
###xml 42 49 42 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF2BP2</italic>
###xml 77 78 77 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 78 79 78 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
Pattern of linkage disequilibrium between IGF2BP2 SNPs. Plot of pairwise SNP r2 values calculated from control genotype data. The plot was drawn to scale using LocusView (T. Petryshen, A. Kirby, M. Ainscow, unpublished software).
###end p 33
###begin p 34
###xml 36 43 36 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF2BP2</italic>
###xml 213 214 213 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 228 229 228 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 247 248 247 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 251 252 251 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 264 265 264 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Q</italic>
###xml 270 271 270 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">I</italic>
###xml 271 272 271 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 274 276 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
Meta-analysis of the association of IGF2BP2 SNPs with type 2 diabetes. For each study, the point estimate of the OR with 95% CI is shown. In addition, the summary fixed and random effects are shown for rs4402960 (A), rs1470579 (B), and rs9826022 (C). D: Cochran's Q and I2 (12,13) statistics for these three variants.
###end p 34
###begin p 35
###xml 15 22 15 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF2BP2</italic>
###xml 142 143 142 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Association of IGF2BP2 SNPs with type 2 diabetes: confirmed susceptibility SNPs rs4402960 and rs1470579 and SNPs showing nominal association (P < 0.05) in French Caucasians
###end p 35
###begin p 36
###xml 9 10 9 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Data are n (%) unless otherwise indicated.
###end p 36
###begin p 37
###xml 42 49 42 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF2BP2</italic>
###xml 103 104 101 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 104 105 102 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Relative to the NCBI36 coordinates of the IGF2BP2 genomic locus (chr. 3:186,844,221.0.187,025,521). chi2P values are shown.
###end p 37

